Eli Lilly has shared one-year histologic outcomes from a phase 3 study of its interleukin-23p19 antagonist mirikizumab in ...

• Mtech Access – Powered by Petauri™ are excited to be returning to ISPOR Europe this November. The team will be joined by ...

Up to 20% of patients will develop metastatic castration-resistant disease within five to seven years of diagnosis ...

Roche has presented positive two-year results from an ongoing study of its spinal muscular atrophy (SMA) treatment Evrysdi ...

Last chance to register for our exclusive webinar, “Why Patient Perspectives Matter: Driving Success in Clinical Trials”!

Johnson & Johnson’s (J&J) Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care ...

Roche’s PI3K inhibitor Itovebi (inavolisib) has been approved by the US Food and Drug Administration (FDA) as part of a ...

Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare ...

Eli Lilly has partnered with insitro to advance new treatments for metabolic diseases, including metabolic ...

Astellas Pharma and AviadoBio have entered into an exclusive option and licence agreement worth over $2bn for an ...

See more about this new insights product, Medscape AffinityTM, which offers unparalleled insights into the online behaviour of 13M+ HCPs to help you make fully informed decisions around your brand and ...